1 From UC San Diego Moores Cancer Center; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute; City of Hope Comprehensive Cancer Center; Fox Chase Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Massachusetts General Hospital Cancer Center; University of Colorado Cancer Center; Hereditary Colon Cancer Foundation; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Stanford Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; The University of Texas MD Anderson Cancer Center; Moffitt Cancer Center; Mayo Clinic Cancer Center; Fred & Pamela Buffett Cancer Center; Memorial Sloan Kettering Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Vanderbilt-Ingram Cancer Center; Huntsman Cancer Institute at the University of Utah; University of Alabama at Birmingham Comprehensive Cancer Center; University of Wisconsin Carbone Cancer Center; and National Comprehensive Cancer Network.
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal provide recommendations for the management of patients with high-risk syndromes associated with an increased risk of colorectal cancer (CRC). The NCCN Panel for Genetic/Familial High-Risk Assessment: Colorectal meets at least annually to assess comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. These NCCN Guidelines Insights focus on genes newly associated with CRC risk on multigene panels, the associated evidence, and currently recommended management strategies.
Provided content development and/or authorship assistance.